Company Overview of Dermira, Inc.
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinic...
2055 Woodside Road
Redwood City, CA 94061
Founded in 2010
Key Executives for Dermira, Inc.
Dermira, Inc. does not have any Key Executives recorded.
Dermira, Inc. Key Developments
Dermira, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 12 14
Dermira, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, loss from operations was $7.7 million against $4.6 million last year. Net loss was $7.8 million compared to net loss for the quarter ended September 30, 2013 of $4.7 million. Net loss per basic and diluted share was $8.66 against $5.57 last year.
For the nine months, loss from operations was $24.9 million against $15.6 million last year. Net loss was $25.1 million compared to net loss of $15.6 million last year. Net loss per basic and diluted share was $27.93 against $19.40 last year.
Dermira, Inc.(NasdaqGS:DERM) added to NASDAQ Composite Index
Oct 7 14
Dermira, Inc. will be added to the NASDAQ Composite Index.
Dermira, Inc. Auditor Raises 'Going Concern' Doubt
Aug 27 14
Dermira, Inc. filed its Annual on Aug 27, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 19, 2014
August 15, 2014
July 3, 2014
Most Searched Private Companies
Sponsored Financial Commentaries